Ua hoʻolaha ʻo Curative Biotechnology, Inc. i kēia lā ua holomua ka ʻoihana i kāna aʻo ʻana i ka toxicology Good Laboratory Practice (GLP).
Hoʻolālā ʻia ka haʻawina o kēia manawa e ana i ka hiki ke hoʻomanawanui, pharmacokinetics a me nā mea ʻona kūloko a ʻōnaehana paha o ka metformin i hoʻoponopono hou ʻia ke lawelawe ʻia e ka lawe ʻana o ka maka. E nānā pū ka haʻawina i kona puʻunaue ocular tissue.
ʻO ke aʻo ʻana o ka toxicology Good Laboratory Practice (GLP) kahi koi no ka waiho ʻana i ka FDA Investigational New Drug (IND).
Hoʻokomo ʻia ka ʻae ʻana o ka maka i ka nānā ʻana i ka dosing, nā ʻike lapaʻau maʻamau i ʻelua manawa i kēlā me kēia lā (ka loiloi ʻana i ka ʻano/nā hōʻailona clinical me ka nānā pono ʻana i nā maka), nā hoʻokolohua ophthalmic e kekahi ophthalmologist lāʻau i hōʻoia ʻia e ka Papa e like me ka pālākiō helu Hackett-McDonald i hoʻololi ʻia, a me ka histopathology ocular. .
Ma lalo o kahi ʻaelike noiʻi a me ka hoʻomohala ʻana (CRADA), e hui pū ka National Eye Institute (NEI) a me Curative Biotechnology, Inc. (AMD) maʻi.
He aha e lawe ʻia mai kēia ʻatikala:
- Hoʻokomo ʻia ka ʻae ʻana o ka maka i ka nānā ʻana i ka dosing, nā ʻike lapaʻau maʻamau i ʻelua manawa i kēlā me kēia lā (ka loiloi ʻana i ka ʻano/nā hōʻailona clinical me ka nānā pono ʻana i nā maka), nā hoʻokolohua ophthalmic e kekahi ophthalmologist lāʻau i hōʻoia ʻia e ka Papa e like me ka pālākiō helu Hackett-McDonald i hoʻololi ʻia, a me ka histopathology ocular. .
- The current study is designed to gauge tolerability, pharmacokinetics and any local or systemic toxicity of reformulated metformin when administered by topical ocular delivery.
- ʻO ke aʻo ʻana o ka toxicology Good Laboratory Practice (GLP) kahi koi no ka waiho ʻana i ka FDA Investigational New Drug (IND).
